172 related articles for article (PubMed ID: 16450140)
1. Use of 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas.
Galldiks N; Kracht LW; Burghaus L; Thomas A; Jacobs AH; Heiss WD; Herholz K
Eur J Nucl Med Mol Imaging; 2006 May; 33(5):516-24. PubMed ID: 16450140
[TBL] [Abstract][Full Text] [Related]
2. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.
Grosu AL; Weber WA; Franz M; Stärk S; Piert M; Thamm R; Gumprecht H; Schwaiger M; Molls M; Nieder C
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):511-9. PubMed ID: 16168843
[TBL] [Abstract][Full Text] [Related]
3. Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomas.
Roelcke U; Wyss MT; Nowosielski M; Rudà R; Roth P; Hofer S; Galldiks N; Crippa F; Weller M; Soffietti R
Neuro Oncol; 2016 May; 18(5):744-51. PubMed ID: 26578622
[TBL] [Abstract][Full Text] [Related]
4. Trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid (anti-18F-FACBC) is a feasible alternative to 11C-methyl-L-methionine and magnetic resonance imaging for monitoring treatment response in gliomas.
Sasajima T; Ono T; Shimada N; Doi Y; Oka S; Kanagawa M; Baden A; Mizoi K
Nucl Med Biol; 2013 Aug; 40(6):808-15. PubMed ID: 23701701
[TBL] [Abstract][Full Text] [Related]
5. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors.
Jacobs AH; Thomas A; Kracht LW; Li H; Dittmar C; Garlip G; Galldiks N; Klein JC; Sobesky J; Hilker R; Vollmar S; Herholz K; Wienhard K; Heiss WD
J Nucl Med; 2005 Dec; 46(12):1948-58. PubMed ID: 16330557
[TBL] [Abstract][Full Text] [Related]
6. L-(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy.
Grosu AL; Weber WA; Riedel E; Jeremic B; Nieder C; Franz M; Gumprecht H; Jaeger R; Schwaiger M; Molls M
Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):64-74. PubMed ID: 16111573
[TBL] [Abstract][Full Text] [Related]
7. PET With 11C-Methyl-l-Methionine as a Predictor of Consequential Outcomes at the Time of Discontinuing Temozolomide-Adjuvant Chemotherapy in Patients With Residual IDH-Mutant Lower-Grade Glioma.
Beppu T; Iwaya T; Sato Y; Nomura JI; Terasaki K; Sasaki T; Yamada N; Fujiwara S; Sugai T; Ogasawara K
Clin Nucl Med; 2022 Jul; 47(7):569-574. PubMed ID: 35452002
[TBL] [Abstract][Full Text] [Related]
8. Patient-tailored, imaging-guided, long-term temozolomide chemotherapy in patients with glioblastoma.
Galldiks N; Kracht LW; Burghaus L; Ullrich RT; Backes H; Brunn A; Heiss WD; Jacobs AH
Mol Imaging; 2010 Feb; 9(1):40-6. PubMed ID: 20128997
[TBL] [Abstract][Full Text] [Related]
9. 11C-methionine PET as a prognostic marker in patients with glioma: comparison with 18F-FDG PET.
Kim S; Chung JK; Im SH; Jeong JM; Lee DS; Kim DG; Jung HW; Lee MC
Eur J Nucl Med Mol Imaging; 2005 Jan; 32(1):52-9. PubMed ID: 15309332
[TBL] [Abstract][Full Text] [Related]
10. Low c-Met expression levels are prognostic for and predict the benefits of temozolomide chemotherapy in malignant gliomas.
Li MY; Yang P; Liu YW; Zhang CB; Wang KY; Wang YY; Yao K; Zhang W; Qiu XG; Li WB; Peng XX; Wang YZ; Jiang T
Sci Rep; 2016 Feb; 6():21141. PubMed ID: 26879272
[TBL] [Abstract][Full Text] [Related]
11. Amino acid PET tracers are reliable markers of treatment responses to single-agent or combination therapies including temozolomide, interferon-β, and/or bevacizumab for glioblastoma.
Ono T; Sasajima T; Doi Y; Oka S; Ono M; Kanagawa M; Baden A; Mizoi K; Shimizu H
Nucl Med Biol; 2015 Jul; 42(7):598-607. PubMed ID: 25892210
[TBL] [Abstract][Full Text] [Related]
12. Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value.
Van Laere K; Ceyssens S; Van Calenbergh F; de Groot T; Menten J; Flamen P; Bormans G; Mortelmans L
Eur J Nucl Med Mol Imaging; 2005 Jan; 32(1):39-51. PubMed ID: 15309329
[TBL] [Abstract][Full Text] [Related]
13. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients with glioma.
Ullrich RT; Kracht L; Brunn A; Herholz K; Frommolt P; Miletic H; Deckert M; Heiss WD; Jacobs AH
J Nucl Med; 2009 Dec; 50(12):1962-8. PubMed ID: 19910435
[TBL] [Abstract][Full Text] [Related]
14. Imaging of non- or very subtle contrast-enhancing malignant gliomas with [¹¹C]-methionine positron emission tomography.
Galldiks N; Kracht LW; Dunkl V; Ullrich RT; Vollmar S; Jacobs AH; Fink GR; Schroeter M
Mol Imaging; 2011 Dec; 10(6):453-9. PubMed ID: 22201536
[TBL] [Abstract][Full Text] [Related]
15. Use of (11)C-methionine PET parametric response map for monitoring WT1 immunotherapy response in recurrent malignant glioma.
Chiba Y; Kinoshita M; Okita Y; Tsuboi A; Isohashi K; Kagawa N; Fujimoto Y; Oji Y; Oka Y; Shimosegawa E; Morita S; Hatazawa J; Sugiyama H; Hashimoto N; Yoshimine T
J Neurosurg; 2012 Apr; 116(4):835-42. PubMed ID: 22242671
[TBL] [Abstract][Full Text] [Related]
16. Optimization of semi-quantification in metabolic PET studies with 18F-fluorodeoxyglucose and 11C-methionine in the determination of malignancy of gliomas.
Borbély K; Nyáry I; Tóth M; Ericson K; Gulyás B
J Neurol Sci; 2006 Jul; 246(1-2):85-94. PubMed ID: 16603193
[TBL] [Abstract][Full Text] [Related]
17. Association of 11C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme.
Lee IH; Piert M; Gomez-Hassan D; Junck L; Rogers L; Hayman J; Ten Haken RK; Lawrence TS; Cao Y; Tsien C
Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):479-85. PubMed ID: 18834673
[TBL] [Abstract][Full Text] [Related]
18. Early change in glucose metabolic rate measured using FDG-PET in patients with high-grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy.
Charnley N; West CM; Barnett CM; Brock C; Bydder GM; Glaser M; Newlands ES; Swindell R; Matthews J; Price P
Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):331-8. PubMed ID: 16839701
[TBL] [Abstract][Full Text] [Related]
19. Spatial distribution of malignant tissue in gliomas: correlations of 11C-L-methionine positron emission tomography and perfusion- and diffusion-weighted magnetic resonance imaging.
Tietze A; Boldsen JK; Mouridsen K; Ribe L; Dyve S; Cortnum S; Østergaard L; Borghammer P
Acta Radiol; 2015 Sep; 56(9):1135-44. PubMed ID: 25270372
[TBL] [Abstract][Full Text] [Related]
20. 11C-Methionine positron emission tomography for preoperative evaluation of suggestive low-grade gliomas.
Gumprecht H; Grosu AL; Souvatsoglou M; Dzewas B; Weber WA; Lumenta CB
Zentralbl Neurochir; 2007 Feb; 68(1):19-23. PubMed ID: 17487804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
